Chair: Ron van Schaik
Members: Adrian LLerena
The ESPT clinical implementation division collaborates with the European Pharmacogenetics Implementation Consortium (www.eu-pic.net), the IFCC Task Force Pharmacogenetics (www.ifcc.org) and the Committee Molecular Diagnostics of EFLM (www.eflm.org)
Strategic Objectives of Clinical Implementation Division
1. Create a laboratory network that will enable fast knowledge transfer and rapid implementation of new pharmacogenetic tests, ensuring uniformity in testing and reporting
2. Educate healthcare professionals throughout Europe about current status ad upcoming developments in pharmacogenetics
3. Be a partner for industry for advice and implementation of pharmacogenetic based accompanying diagnostics
4. Be a partner for advisory and regulatory bodies, enabling access to a large group of pharmacogenetic experts and clinical expertise and experiences
The Scientific Research Division and Clinical Implementation Division address both scientific research as well as clinical implementation, with the idea that the barrier between these two fields should be low. Both divisions will focus on promoting and facilitating clinical implementation of valuable new pharmacogenetic/genomic biomarkers. For this, specific working groups will be formed.
Enhance research on, and facilitate clinical implementation of personalised medicine for patient care
ESPT believes that a major problem for clinical implementation of personalized medicine, particularly pharmacogenetics/genomics, is that the field is not sufficiently organized at this moment. Clinicians and patients should be able to benefit from the knowledge we have accumulated today for guiding individual drug therapy. Therefore, ESPT has a strong focus translation. We aim to promote this process by offering a powerful organization that brings together experts in the field.
Actions of the division
1. Identify among ESPT members individuals that have experience in clinical implementation and are interested to join discussion on these topics
2. Identify with this working group barriers for clinical implementation and suggest solutions to overcome these